EuroBiotech: More Articles of Note

> Active Biotech (STO:ACTI) revealed it is looking for a partner to develop tasquinimod in multiple myeloma. Tasquinimod, which was being developed as a treatment for prostate cancer before weak Phase III data scuttled its prospects, has undergone preclinical testing in multiple myeloma, putting Active Biotech in a position to file for patent protection through to 2035. Active Biotech plans to file orphan drug applications for tasquinimod in the indication in the U.S. and Europe this year, which, if successful, would boost the prospects of a program it thinks could play a role in future combination therapies. Release

> Onxeo (OMX:ONXEO) set up a U.S. subsidiary. The subsidiary, which is working out of New York, is tasked with supporting Onxeo as it expands its development programs and seeks to tighten its ties to scientific and financial institutions in the U.S. Philippe Maitre, who has previously served as CEO of biotechs including Aventis spin out Anosys, will head up the U.S. operation. "Philippe ... [has] particular expertise in finance, business development and mergers and acquisitions," Onxeo CEO Judith Greciet said in a statement. Release

> Johnson & Johnson ($JNJ) struck a deal to test the the CD38 antibody it licensed from Genmab (CPH:GEN) in combination with Genentech's anti-PD-L1 antibody atezolizumab. As a result of the pact, J&J will kick off a Phase Ib trial of the combination in solid tumors, while Roche's ($RHHBY) Genentech will take charge of a multiple myeloma study. The trials add to the slate of studies of Genmab's Darzalex, which won FDA approval in multiple myeloma last year. FierceBiotech I Release

> UniQure ($QURE) committed to further testing the potential for gene therapy AMT-130 to silence the Huntingtin gene (HTT). An inherited, mutated form of HTT causes the fatal neurodegenerative disorder Huntington's disease. To date, uniQure has generated preclinical proof-of-concept data that it thinks indicate AMT-130 has the potential to silence HTT in one shot. UniQure is now working to generate more data to support the hypothesis ahead of a planned IND filing. Statement

> MolMed (BIT:MLM) teamed up with fellow Milanese biotech Genenta Science to develop a gene therapy against multiple myeloma. The deal will see MolMed develop and validate manufacturing and analytical methods for the gene therapy ahead of planned clinical trials. "The aim of Genenta Science is to rapidly translate the preclinical results of its gene therapy approach against tumors to the patients," Genenta CEO Pierluigi Paracchi said in a statement. Release

> Moberg Pharma (OMX:MOB) landed an agreement with Cadila Pharmaceuticals for the late-phase development of its lozenge formulation of bupivacaine, BUPI. Having inked the deal, Cadila will run a Phase III trial of the lozenge in India. Moberg has signed over the rights to commercialize BUPI in India and Africa, with the exception of South Africa, to Cadila. And, while neither party has disclosed the financials of the deal, Moberg has revealed the agreement will "substantially" cut the amount it needs to fork over for further development of the treatment for pain in oral mucositis patients. Release I More

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.